Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2025)
Supernus Pharmaceuticals (SUPN) reported Return on Capital Employed of 5.67% for Q4 2025, down 1335.0% year-over-year from 0.46% in Q4 2024, and down 64.37% quarter-over-quarter from 3.45% in Q3 2025.
Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 14 years of Return on Capital Employed data on file, last reported at 5.67% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 5.67%, down 1335.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 5.67% (down 1335.0% YoY), and the FY2025 annual result was 5.81%, down 1373.0% from the prior year.
- Return on Capital Employed retreated to 5.67% in Q4 2025 per SUPN's latest filing, from 3.45% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.48% in Q1 2021 and troughed at 5.67% in Q4 2025.
- A 5-year average of 4.24% and a median of 5.14% in 2022 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 832 bps in 2025 and fell as far as 1335 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 6.58% in 2021, then plunged by 31 bps to 4.57% in 2022, then tumbled by 112 bps to 0.53% in 2023, then soared by 1545 bps to 7.68% in 2024, then tumbled by 174 bps to 5.67% in 2025.
- Business Quant data shows SUPN's Return on Capital Employed at 5.67% in Q4 2025, 3.45% in Q3 2025, and 5.95% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Supernus Pharmaceuticals | 2.63 Bn | 2.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.67% |
| Sep 30, 2025 | -3.45% |
| Jun 30, 2025 | 5.95% |
| Mar 31, 2025 | 6.93% |
| Dec 31, 2024 | 7.68% |
| Sep 30, 2024 | 5.71% |
| Jun 30, 2024 | 2.65% |
| Mar 31, 2024 | -1.39% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | 3.00% |
| Jun 30, 2023 | 1.58% |
| Mar 31, 2023 | 4.86% |
| Dec 31, 2022 | 4.57% |
| Sep 30, 2022 | 1.85% |
| Jun 30, 2022 | 5.58% |
| Mar 31, 2022 | 5.42% |
| Dec 31, 2021 | 6.58% |
| Sep 30, 2021 | 9.25% |
| Jun 30, 2021 | 11.65% |
| Mar 31, 2021 | 12.48% |